Previous Close | 34.03 |
Open | 33.94 |
Bid | 33.05 x 200 |
Ask | 33.14 x 400 |
Day's Range | 32.88 - 33.94 |
52 Week Range | 17.53 - 59.84 |
Volume | |
Avg. Volume | 866,974 |
Market Cap | 2.538B |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.69 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28.27 |
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating